Zobrazeno 1 - 10
of 662
pro vyhledávání: '"BO LAN"'
Autor:
Qi Zhao, Mingxia Jiang, Jiaxuan Liu, Mengqi Zhang, Maiyue He, Shihan Zhou, Jiani Wang, Hongnan Mo, Bo Lan, Peng Yuan, Pin Zhang, Fei Ma, Qiao Li, Binghe Xu
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 10, Pp 934-950 (2024)
Objective: CDK4/6 inhibitors (CDK4/6is) in combination with endocrine therapy have secured a central role in the treatment of hormone receptor (HR)-positive advanced breast cancer (ABC) and have transformed the therapeutic landscape. Cross-line CDK4/
Externí odkaz:
https://doaj.org/article/c9c740e3411248cc8774561a0b366f25
Publikováno v:
Genome Biology, Vol 25, Iss 1, Pp 1-25 (2024)
Abstract Numerous plant taxa are threatened by habitat destruction or overexploitation. To overcome these threats, new methods are urgently needed for rescuing threatened and endangered plant species. Here, we review the genetic consequences of threa
Externí odkaz:
https://doaj.org/article/9ea2a711ffed44dda667994a5c8bc6d9
Autor:
Jiaxuan Liu, Maiyue He, Mingxia Jiang, Shihan Zhou, Mengqi Zhang, Yiqun Li, Shanshan Chen, Ruigang Cai, Hongnan Mo, Bo Lan, Fei Ma, Binghe Xu, Qiao Li
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Exploration of novel combination mode of pyrotinib and chemotherapy for heavily pretreated HER2-positive metastatic breast cancer (MBC) and how to balance survival benefits and compliance are still urgent problems in clinical prac
Externí odkaz:
https://doaj.org/article/7f027f026be5409096c94cd702688cf3
Autor:
Shuning Liu, Bo Lan, Yuanyi Wang, Tao Yang, Lixi Li, Hewei Ge, Cheng Zeng, Binghe Xu, Haili Qian, Fei Ma
Publikováno v:
EBioMedicine, Vol 109, Iss , Pp 105379- (2024)
Summary: Background: The PHILA study suggests that pyrotinib, trastuzumab, and docetaxel significantly improved progression-free survival (PFS) compared with placebo, trastuzumab, and docetaxel in patients with untreated HER2-positive metastatic brea
Externí odkaz:
https://doaj.org/article/9bb421ef3cf74b95b5cb31e0773cfbb1
Publikováno v:
Breast, Vol 77, Iss , Pp 103766- (2024)
Background: Clinical research competence determines the quality of clinical research and the reliability of research findings. We aimed to explore the clinical research implementation capabilities of breast cancer treatment departments in China. Meth
Externí odkaz:
https://doaj.org/article/49cd89dcf0ad496a9ba115a260f934c2
Autor:
Mingxia Jiang, Jiaxuan Liu, Maiyue He, Mengqi Zhang, Shihan Zhou, Shanshan Chen, Ruigang Cai, Hongnan Mo, Bo Lan, Pin Zhang, Binghe Xu, Qiao Li
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Inetetamab is a novel antibody targeting human epidermal growth factor receptor 2 (HER2) developed in China. Due to its optimized antibody-dependent cell-mediated cytotoxicity effect compared with trastuzumab, it has shown good efficacy a
Externí odkaz:
https://doaj.org/article/84df8beb4c8646e5827cc01f438d0280
Publikováno v:
Frontiers in Plant Science, Vol 15 (2024)
Root rot is a major disease that causes decline of alfalfa production, and Fusarium is a major pathogen associated with root rot. In this study, 13 Fusarium isolates were obtained from alfalfa with root rot in Gansu Province, the major alfalfa produc
Externí odkaz:
https://doaj.org/article/9038f4b56f6e4596894a36f8202386fe
Publikováno v:
IEEE Access, Vol 12, Pp 145511-145521 (2024)
This paper introduces a neural network model for seismic phase picking tailored for edge intelligence. The model architecture is meticulously designed to accommodate the resource constraints of edge computing platforms, enabling real-time seismic pha
Externí odkaz:
https://doaj.org/article/e04d1c36ebbb48ae952a4767ac96c246
Publikováno v:
Cancer Innovation, Vol 2, Iss 5, Pp 319-322 (2023)
Externí odkaz:
https://doaj.org/article/3ca98779dff24331b0b8a8d2590ebe16
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background This study sought to compare the benefits and safety of agents including Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors, and histone deacetylase (H
Externí odkaz:
https://doaj.org/article/5b1d6c4b473245a1b5f4d4efb599281d